MedPacto, Inc. (235980.KQ) KOE
Currency In KRW
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
MedPacto, Inc.
Address
Borim Building
Seoul, 06668
Korea (the Republic of)
Phone
82 2 6938 0200
Website
Sector
Healthcare
Industry
Biotechnology
Employees
56
First IPO Date
December 19, 2019
Key Executives
| Name | Title | Pay | Year Born |
| Seong-Jin Kim | Founder & Chief Executive Officer | 0 | N/A |
| Ki Baik Hahm | Executive Vice President of R&D | 0 | N/A |
| Timothy R. Allen | Executive Vice President of Clinical Development at MedPacto Therapeutics - U.S. | 0 | N/A |
| Sunjin Hwang | Chief Medical Officer | 0 | N/A |
| Jungwon Woo | President | 0 | N/A |
AD
Description
MedPacto, Inc. is a South Korean biopharmaceutical company specializing in the research and development of novel therapeutic solutions for oncology and autoimmune conditions. The firm's pipeline includes several key drug candidates: ME-1601mAb, an investigational treatment designed to target BSP1 for various cancers; MS-1601A, which addresses both cancerous and autoimmune diseases by targeting TRG1; and vactosertib, a therapeutic candidate aimed at solid tumors. MedPacto is headquartered in Seoul, South Korea.
AD
